Generated by AI
The Defiance Daily Target 2X Long MRNA ETF is a leveraged exchange-traded fund designed to deliver daily investment results, before fees and expenses, equivalent to two times (200%) the daily percentage change in the share price of Moderna, Inc. (NASDAQ: MRNA). Issued by Defiance ETFs LLC, this actively managed, non-diversified fund employs derivatives such as swap agreements and listed options contracts to achieve its amplified exposure to Moderna's stock performance. Launched on February 4, 2026, it targets traders seeking tactical opportunities in the mRNA biotechnology sector, where Moderna plays a pivotal role in messenger RNA-based therapeutics and vaccines. With an expense ratio of 1.31%, the ETF distributes returns and operates within the trading-leveraged equity category, providing concentrated bullish leverage on Moderna's innovations in genetic medicine. It serves as a specialized tool for market participants aiming to capitalize on short-term movements in biotechnology trends tied to mRNA technology advancements. Custodied by U.S. Bank N.A., the fund underscores Defiance's focus on innovative ETF strategies amid evolving biotech landscapes.
Summary of Aug 20's posts. Generated by AI.
No summary yet.
Summary of Aug 19's posts. Generated by AI.
No summary yet.
Summary of Aug 20's posts. Generated by AI.
Investors talking about MRNX also mention these. Each card shows that asset’s own numbers for the past 24 hours.